Press Releases

Featured Press Releases

BIO Applauds Introduction of Bipartisan…

BIO President and CEO John F. Crowley today released the following statement after a bipartisan group of Senators, Sen. Bob Casey (D-PA), Sen. Markwayne Mullin (R-OK), Sen. Sherrod Brown (D-OH), and Sen. Susan Collins (R-ME), introduced the Creating…

Learn more

BIO International Convention Celebrates Another…

Biotechnology Innovation Organization (BIO) is proud to conclude the 2024 BIO International Convention in San Diego, held last week June 3-6, 2024. 1,400 exhibitors and more than 19,500 attendees from 70 countries came together for four full days of…

Learn more

BIO Recognizes Industry Leaders for…

WASHINGTON - June 5, 2024 – The Biotechnology Innovation Organization (BIO) today announced the winners of the organization’s 2024 Leadership in Agri-Biotechnology Awards — honoring Dr. Annette Kleiser, CEO of Dalan Animal Health, as the recipient…

Learn more

BIO Encourages Science-based Oversight for Animal and Plant Biotech as Dr. Califf Takes Helm at FDA

February 15, 2022

The following statement may be attributed to BIO's Vice President for Agriculture and Environment Sarah Gallo: “BIO looks forward to working with a proven leader like Dr. Califf as he takes the helm at FDA. Dr. Califf will lead an…

BIO Statement on Confirmation of Dr. Califf to Lead FDA

February 15, 2022

Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), made the following statement after Dr. Robert Califf was confirmed by the Senate to lead the Food and Drug Administration (FDA): “We congratulate Dr…

New BIO Report Examines the State of Antibacterial Innovation

February 14, 2022

Current pipeline “insufficient” to meet the threat of AMR, policy reforms critically needed The Biotechnology Innovation Organization (BIO) today released a new report examining antibacterial innovation and the current pipeline for new…

BIO Stands United with the President's Goal of Ending Cancer

February 2, 2022

The following statement can be attributed to BIO's President and CEO Dr. Michelle McMurry-Heath: “President Biden has long been a champion of research to end cancer. He reaffirmed that commitment today with the relaunch of the "Cancer Moonshot." …

New Report Outlines Best Practices in Bioscience Economic Development Initiatives

January 20, 2022

Today, the Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released a new report on bioscience economic development best practices, “Driving the Bioscience Economy Forward During…

CMS’ Attempt to Restrict Patient Access to Alzheimer’s Drug Sets “Dangerous and Far-Reaching” Precedent

January 13, 2022

Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS) proposed National Coverage Determination (NCD) to…

"Build Back Better Act" Drug Pricing Provisions Weaken U.S. Innovation Ecosystem, Hurt Patients

November 19, 2021

Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement after the House of Representatives passed the Build Back Better Act: “The legislation that passed the House today…

Patients Empowered with New “Clinical Trials: The Power of Participation” Website

November 16, 2021

The Biotechnology Innovation Organization (BIO) today announced the launch of Clinical Trials: The Power of Participation (CTPoP), a website that addresses how clinical trials work, how to enroll in a clinical trial, and what to expect as a clinical…

White House’s “Build Back Better” Plan Builds New Barriers for Patients and Scientists Discovering Groundbreaking Cures

November 4, 2021

Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), made the following statement: "Last week, Democratic leaders announced they had reached a drug pricing “deal.” We wanted to see the details before…

Proposed Prescription Drug User Fee Act VII Performance Goals Letter Earns BIO Support

August 24, 2021

Biotechnology Innovation Organization (BIO) Chief Scientific Officer, E. Cartier Esham issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VII performance goals letter: “The Prescription Drug User Fee…

Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy.